Abstract | PURPOSE: METHODS: The clinical data of 134 newly diagnosed NSCLC patients were retrospectively reviewed. CC was defined as a body weight loss >5 or >2 % in patients with a body mass index of <20 kg/m(2). CC was assessed at baseline (T1) and 3 months (T2), 6 months (T3), and 12 months (T4) after chemotherapy initiation. Skeletal muscle mass was assessed using the lumber skeletal muscle index (LSMI). RESULTS: The proportion of patients with CC at T1, T2, T3, and T4 was 45.6, 46.1, 25.5, and 26.0 %, respectively. The frequency of grade 3 chemotherapy-induced anorexia was higher in patients with CC than those without CC at T2 (15.4 vs. 0.0 %, P = 0.0044). At all time points, patients with CC had shorter survival times than those without CC. Patients with low LSMIs (men, <41 cm(2)/m(2); women, <38 cm(2)/m(2)) tended to have poor prognosis. Adjusted Cox proportional hazard ratios and corresponding confidence intervals for CC at T1, T2, T3, and T4 were 2.53 (1.33-4.88), 1.97 (1.27-3.06), 3.86 (2.14-6.81), and 1.62 (0.80-3.16), respectively. CONCLUSION: CC presence and decreased skeletal muscle mass are associated with poor prognosis in advanced NSCLC patients receiving chemotherapy.
|
Authors | Madoka Kimura, Tateaki Naito, Hirotsugu Kenmotsu, Tetsuhiko Taira, Kazushige Wakuda, Takuya Oyakawa, Yasushi Hisamatsu, Takaaki Tokito, Hisao Imai, Hiroaki Akamatsu, Akira Ono, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Keita Mori, Toshiaki Takahashi, Nobuyuki Yamamoto |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 23
Issue 6
Pg. 1699-708
(Jun 2015)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 25430482
(Publication Type: Journal Article)
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Body Mass Index
- Cachexia
(epidemiology, mortality)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality, pathology)
- Female
- Humans
- Lung Neoplasms
(drug therapy, mortality, pathology)
- Male
- Middle Aged
- Muscle, Skeletal
(physiology)
- Prognosis
- Retrospective Studies
- Sarcopenia
(epidemiology, mortality)
- Weight Loss
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|